BetterLife Pharma Inc (NPAU) - Total Liabilities
Based on the latest financial reports, BetterLife Pharma Inc (NPAU) has total liabilities worth €6.04 Million EUR (≈ $7.06 Million USD) as of July 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BetterLife Pharma Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how BetterLife Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See BetterLife Pharma Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
BetterLife Pharma Inc Competitors by Total Liabilities
The table below lists competitors of BetterLife Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mecanica Sa Ce
RO:MECF
|
Romania | RON11.53 Million |
|
Maschinenfabrik HEID AG
VI:HED
|
Austria | €54.61K |
|
Nippon Active Value Fund Plc
LSE:NAVF
|
UK | GBX671.00K |
|
Strike Resources Ltd
AU:SRK
|
Australia | AU$812.49K |
|
Induct AS
OL:INDCT
|
Norway | Nkr14.77 Million |
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
USA | $793.06K |
|
Adalta Ltd
AU:1AD
|
Australia | AU$2.07 Million |
|
Gencell Ltd
TA:GNCL
|
Israel | ILA2.90 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down BetterLife Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NPAU company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 26.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BetterLife Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BetterLife Pharma Inc (2017–2025)
The table below shows the annual total liabilities of BetterLife Pharma Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | €7.59 Million ≈ $8.87 Million |
-5.40% |
| 2024-01-31 | €8.02 Million ≈ $9.38 Million |
+5.42% |
| 2023-01-31 | €7.61 Million ≈ $8.89 Million |
+50.89% |
| 2022-01-31 | €5.04 Million ≈ $5.89 Million |
-15.24% |
| 2021-01-31 | €5.95 Million ≈ $6.95 Million |
+6.34% |
| 2020-01-31 | €5.59 Million ≈ $6.54 Million |
+9.99% |
| 2019-01-31 | €5.09 Million ≈ $5.95 Million |
+860.55% |
| 2018-01-31 | €529.51K ≈ $619.06K |
-74.86% |
| 2017-01-31 | €2.11 Million ≈ $2.46 Million |
-- |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more